Fischer Medical Ventures Surges 2.5% After Securing $10 Mn Indonesia Healthcare Deal

Chennai, July 11, 2025: Fischer Medical Ventures Ltd (NSE: FISCHER, BSE: 524743) saw its share price increase by 2.50% to ₹795.25 as of 9:50 AM today, following the announcement of a strategic partnership with the City of Jember, Indonesia. This significant deal aims to support tuberculosis (TB) eradication efforts using portable AI-powered X-ray systems, with an estimated value of over USD 10 million to be executed over two years.

The scrip opened at ₹804.00 and touched an intraday low of ₹786.90. It’s noteworthy that the stock marked both its 52-week high of ₹839.90 and 52-week low of ₹770.10 on July 10, 2025, the day of its listing, reflecting considerable price volatility in its initial trading.

What is Tuberculosis (TB)?

Tuberculosis (TB) is a serious infectious disease caused by a bacterium called Mycobacterium tuberculosis. It primarily affects the lungs (pulmonary TB) but can also affect other parts of the body, such as the spine, brain, kidneys, and lymph nodes (extrapulmonary TB). TB is spread through the air when people with active pulmonary TB cough, sneeze, or speak, releasing tiny droplets containing the bacteria.

AI-Powered X-Ray Systems for TB Detection

AI-powered X-ray systems for TB detection leverage artificial intelligence and machine learning algorithms to analyse chest X-ray images. These systems are designed to:

• Rapidly identify signs of TB: AI can quickly scan X-rays and highlight potential abnormalities suggestive of TB, often faster than a human radiologist.
• Improve accessibility: Portable AI-enabled X-ray machines can be deployed in remote areas, mobile clinics, or regions with a shortage of trained radiologists, making screening more accessible to vulnerable populations.
• Enhance efficiency: They can help triage cases, allowing healthcare professionals to prioritise individuals who need immediate follow-up diagnostics, thereby streamlining the diagnostic workflow.
• Support mass screening: Their speed and efficiency make them suitable for large-scale TB screening programmes.

Key Market Data (as of 09:50 IST, July 11, 2025)

Trade Snapshot

The stock is now officially listed and actively trading in the Medical Equipment & Supplies segment. The surge in market interest follows Fischer Medical Ventures’ announcement of its Indonesian initiative, under which the company will deploy AI-integrated X-ray systems specifically designed for early TB detection in remote and underserved areas.

Financial Snapshot

In terms of financial performance, Fischer Medical Ventures Ltd reported a revenue of ₹49.32 crore for Q4 FY2024-25, marking a significant 131.98% jump compared to the same period last year. On a quarterly basis, revenue saw an even more substantial increase of 306.6% from the previous quarter. However, the company’s net profit for Q4 FY2024-25 stood at ₹1.50 crore, which represents a 42.08% decline compared to the same period last year. Its net profit margin for the quarter was 3.04%. For the full fiscal year ended March 2025, the consolidated total revenue was ₹112.19 crore with a net profit of ₹1.21 crore, indicating a 34.28% decrease in PAT compared to the previous fiscal year.

Road Ahead For Fischer Medical Ventures

Fischer Medical Ventures’ $10 million Indonesia deal positions it strongly in the global healthcare tech space. The deployment of AI-powered portable X-ray systems for TB detection could drive new international revenue and expand its footprint in underserved markets. While revenue growth is impressive, profit margins remain thin at just over 3%. The company must now focus on improving margins and scaling efficiently. Strong execution and follow-up contracts will be crucial for sustained investor confidence.

About the Company:

Fischer Medical Ventures Ltd, formerly Fischer Chemic Ltd, is a listed company engaged in advanced medical imaging technologies. Its shares are actively traded on both NSE (Symbol: FISCHER) and BSE (Scrip Code: 524743). The company recently made its public debut on July 10, 2025.

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations